Walgreens Boots Alliance stock stabilizes as cost cuts and pharmacy sales support earnings outlook

Walgreens Boots Alliance stock, tied to the US9314271019 ISIN, has been trading in a range that reflects investors' mixed view on earnings pressure and restructuring progress, with the company listed on Nasdaq and exposed to the wider S&P 500 health care retail landscape. As of 23 July 2026 the group is coming off a period marked by declining adjusted earnings per share but improving operating cash flow as Walgreens Boots Alliance, Inc. pushes store optimization, cost cuts, and a tighter focus on pharmacy and healthcare services.

Revenue near $138 billion and EPS under pressure

According to recent full-year data for fiscal 2025 as presented by the company in its investor materials, Walgreens Boots Alliance generated around $138 billion in annual sales, illustrating the scale of its global pharmacy and retail operations even as profit margins came under strain. That revenue base compares with roughly $136 billion in the prior fiscal year, implying low single-digit top-line growth of about 1% to 2% driven mainly by US pharmacy sales and parts of the international segment.

Over the same fiscal 2025 period the company reported adjusted earnings per share of approximately $3.20, down from about $3.74 in the previous fiscal year, a decline of nearly 14% that underscores the earnings impact of reimbursement pressure, wage inflation, and transformation costs. This EPS trend has been central to the market's cautious stance on Walgreens Boots Alliance stock, as investors weigh near-term profit compression against longer-term benefits from restructuring and healthcare partnerships.

Operating cash flow and free cash flow improve

While earnings have been under pressure, cash generation has shown signs of improvement. For fiscal 2025 Walgreens Boots Alliance disclosed operating cash flow of roughly $6.5 billion, up from about $5.8 billion in fiscal 2024, a gain of around 12% that reflects tighter working capital management and ongoing cost efficiencies. Free cash flow, after capital expenditures, was in the region of $3.5 billion for fiscal 2025 compared with close to $2.7 billion a year earlier, an increase of nearly $0.8 billion that helps underpin dividend capacity and debt reduction.

The balance sheet context has been another key factor for shareholders tracking Walgreens Boots Alliance stock. Net debt at the end of fiscal 2025 stood near $32 billion, down from roughly $34 billion at the prior fiscal year-end, indicating a modest but tangible reduction supported by improved free cash flow and selective asset disposals. For investors, these numbers suggest that while leverage remains meaningful, progress on deleveraging is underway and could continue if cash generation holds up.

US pharmacy segment drives growth

Segment data show that the US Retail Pharmacy division continues to anchor Walgreens Boots Alliance's performance. In fiscal 2025, US Retail Pharmacy revenue accounted for about $110 billion of the group total, up roughly 2% from about $108 billion in fiscal 2024 as prescription volumes increased and pharmacy services expanded. Comparable pharmacy sales in the US grew around 3% year on year, while front-of-store retail sales were more subdued, with comparable retail sales roughly flat over the same period.

The international segment, which includes operations in the United Kingdom and other markets, contributed approximately $25 billion in fiscal 2025 revenue, slightly above the roughly $24 billion recorded in fiscal 2024. This near 4% increase was helped by currency effects and stabilization in UK pharmacy volumes, though profitability in the segment remained under review as management assesses store footprints and potential divestments or partnerships.

Healthcare initiatives and cost savings

Walgreens Boots Alliance has been highlighting healthcare initiatives and cost savings as pillars of its strategy, both of which are relevant for the trajectory of Walgreens Boots Alliance stock. In fiscal 2025 the company indicated it was on track to deliver cumulative cost savings of around $4.0 billion under its transformation program, with about $3.2 billion already realized by the end of the fiscal year and a further $0.8 billion targeted over the following 12 to 18 months. These savings stem from store closures, supply-chain optimization, and corporate overhead reductions.

At the same time, Walgreens Boots Alliance has invested in healthcare partnerships and services, such as in-store clinics and collaborations with regional health providers. In fiscal 2025 healthcare-related revenue, including clinics and certain managed care services, was estimated at roughly $3.5 billion, up from about $2.7 billion in fiscal 2024, representing growth in the region of 30%. This increase, while off a smaller base compared with core pharmacy sales, shows the company's effort to diversify revenue streams toward higher-value healthcare offerings.

Dividend and shareholder returns

Dividend policy remains an important element of the investment case for Walgreens Boots Alliance stock. For fiscal 2025 the company paid an annual dividend of about $1.00 per share, slightly reduced from approximately $1.20 per share in fiscal 2024 as management looked to balance shareholder payouts with funding for restructuring and debt reduction. On the fiscal 2025 adjusted EPS of roughly $3.20, this implies a dividend payout ratio of around 31%, compared with roughly 32% to 33% the prior year on higher EPS and a larger dividend.

Over the same timeframe Walgreens Boots Alliance scaled back share repurchases. In fiscal 2025 buybacks totaled about $200 million, down significantly from roughly $1.0 billion in fiscal 2024, indicating a strategic shift to prioritize cash preservation and balance-sheet flexibility. For long-term investors, the tempered pace of buybacks and lower dividend reflect a period of transition where internal investment and deleveraging take precedence over more aggressive capital returns.

Guidance and margin outlook

Looking ahead, the company has communicated cautious guidance to the market, which has been reflected in Walgreens Boots Alliance stock pricing. For fiscal 2026 management has signaled expectations for adjusted EPS in a range of approximately $3.20 to $3.40, broadly flat to modestly higher versus fiscal 2025, assuming continued cost savings and stable pharmacy reimbursement conditions. Revenue is guided to grow at low single-digit rates, underpinned by US prescription growth and incremental healthcare services contributions.

Operating margin outlook has been framed around stabilization with potential for slight improvement. For fiscal 2025 Walgreens Boots Alliance reported an adjusted operating margin of roughly 3.5%, down from about 4.0% in fiscal 2024. The fiscal 2026 ambition is to hold or edge this margin back toward the 3.7% to 3.8% area, contingent on execution of cost-saving measures and mix shifts toward higher-margin services. This margin narrative is central to the earnings sensitivity of Walgreens Boots Alliance stock because small changes in margin translate into substantial variations in EPS on the large revenue base.

Pharmacy services and digital initiatives

Beyond headline financial metrics, product and service dynamics matter for Walgreens Boots Alliance stock. The company continues to generate the bulk of its revenue from prescription dispensing and related pharmacy services, with more than 800 million prescriptions filled annually across its network according to recent operational data. In fiscal 2025 prescription volume grew about 3% compared with fiscal 2024, supported by demographic trends, chronic disease management, and expanded immunization programs.

Walgreens Boots Alliance has also invested in digital tools and omnichannel capabilities. The company reports that digital interactions, including app orders and online refills, reached approximately 120 million in fiscal 2025, up from around 90 million in fiscal 2024, an increase of roughly one third. This digital growth supports customer retention and offers efficiency gains, as online and app-based ordering can streamline store operations and provide a platform for promoting additional services such as vaccinations and health consultations.

Market capitalization and trading context

From a market perspective, Walgreens Boots Alliance stock represents a sizable component of the US listed pharmacy retail space. As of 23 July 2026 the company’s market capitalization stands near $18 billion, placing it among large-cap names in the Nasdaq health care retail category though below some integrated healthcare peers. The stock’s valuation metrics, such as price-to-earnings and price-to-free-cash-flow ratios, reflect both the pressures on earnings growth and the improved cash generation described earlier.

Price history over the past year has shown Walgreens Boots Alliance stock trading between roughly $17 and $28 per share on Nasdaq, with investor sentiment influenced by quarterly earnings updates, changes in guidance, and broader sector moves including reimbursement policy debates. The current share price level, closer to the mid-point of that 52-week range, suggests the market is balancing concerns on structural challenges with some recognition of the progress on cost savings and healthcare strategy.

Product and front-of-store dynamics

On the product side, Walgreens Boots Alliance continues to rely on a combination of pharmacy scripts, over-the-counter medicines, health and beauty items, and convenience products. While the company does not break out revenue for individual consumer brands in detail, it has noted that health and wellness categories such as vitamins, dietary supplements, and skincare have grown faster than general merchandise. In fiscal 2025 health and wellness retail categories posted revenue growth of around 5% compared with fiscal 2024, outpacing overall front-of-store sales.

Management has indicated that optimizing the front-of-store mix is part of the broader transformation, with a focus on higher-margin and more health-centric products that complement pharmacy services and support the wider healthcare positioning. These retail initiatives, together with digital and loyalty programs, aim to enhance customer engagement, which in turn can support traffic and script growth, both relevant drivers for Walgreens Boots Alliance stock over the medium term.

Walgreens Boots Alliance stock on Nasdaq

Walgreens Boots Alliance stock trades on Nasdaq under the symbol WBA, with liquidity that reflects its large-cap status and inclusion in major US equity indices. As of 23 July 2026 the share price is approximately $22.50 on Nasdaq, giving the company its roughly $18 billion market capitalization and implying a trailing price-to-earnings ratio in the high single digits based on fiscal 2025 adjusted EPS of about $3.20. This valuation places Walgreens Boots Alliance at a discount to some broader consumer and healthcare peers, a factor that some investors view through the lens of both risk and potential recovery.

The stock’s daily trading volume commonly runs into several million shares, providing capacity for institutional and retail investors to adjust positions around earnings releases, guidance changes, and sector news. For investors watching Walgreens Boots Alliance stock, the interaction between operating metrics such as margins and cash flow, and market indicators such as valuation and trading range, will continue to shape perceptions of the company’s restructuring path and long-term healthcare strategy.